The Influence of Alpha Kinase 2 Expression on Prognosis in Serous Ovarian Cancer Liver Metastasis

Table 2

Overall survival analyses of OCLM patients.

Variables	Cases	OS (months)	3 year OS (%)	value
	(n = 49)	Mean ± S.D.
Age (years)				0.019
≤60 yrs	21	43.9 ± 4.4	67.5
>60 yrs	28	25.8 ± 4.3	29.3
Laterality				0.885
Unilateral	13	35.2 ± 7.0	64.3
Bilateral	36	35.3 ± 4.1	44.8
Lymph node status				0.827
Negative	19	34.8 ± 5.8	50.5
Positive	30	35.3 ± 4.4	47.7
Chemotherapy				0.743
Yes	40	34.8 ± 3.6	45.4
No	9	37.2 ± 9.7	64.8
ALPK2 expression				0.027
Low	24	41.4 ± 3.9	62.5
High	25	25.1 ± 5.2	24.1

OCLM, ovarian cancer liver metastases; ALPK2, alpha kinase 2. Note. Data were tested by the two-sided log-rank test ^∗P < 0.05 with statistical significance.